EXPLANATORY VERSUS PRAGMATIC APPROACH IN CONTROLLED CLINICAL TRIALS, WITH SPECIAL REFERENCES TO CLINICAL TRIALS OF PLATELET-ACTIVE DRUGS

作者: E. Eschwege , D. Schwartz

DOI: 10.1007/978-3-642-81753-3_22

关键词: Outcome (game theory)Clinical PracticeAlternative medicineValue (ethics)Management scienceMedicineClinical trialComparative trialMedical physics

摘要: A comparative trial may be undertaken with more than one aim in view. One type of objective is to ascertain whether a new treatment actually possesses the favourable activity man which laboratory studies have led expect. This typical situation drug or use for an old drug. In this case, clinical trial, motivated by same research-orientated attitude that experimentation, requires “top” conditions. Another assess practical value relation other treatments: advantages and drawbacks various possible treatments taken into account view making recommendation practice. The aimed at providing practising clinicians basis decisions concerning choice therapy, its motivation strictly nature. Finally, explanatory pragmatic problem formulation determining treatment, patients, criteria methods comparison. trials platelet-active drugs coronary cerebro-vascular diseases, started completed last ten years, are discussed on these two different approaches. Their was demonstrate efficacy all had design. However, most them, purely assessing outcome could explain questionable unsatisfying conclusions they ended. These examples show necessity unambiguous corresponding design tria.They underline importance strategy priorities trials.

参考文章(16)
Corrigan Tp, Fossard Dp, Sutherland I, Thirwell J, Kakkar Vv, Prevention of Fatal Postoperative pulmonary embolism by low doses of heparin. Reappraisal of results of international multicentre trial. The Lancet. ,vol. 1, pp. 567- ,(1977)
V.V. Kakkar, C.T. Howe, A.N. Nicolaides, J.T.G. Renney, M.B. Clarke, Deep vein thrombosis of the leg American Journal of Surgery. ,vol. 120, pp. 527- 530 ,(1970) , 10.1016/S0002-9610(70)80023-X
P.C. Elwood, P.M. Sweetnam, ASPIRIN AND SECONDARY MORTALITY AFTER MYOCARDIAL INFARCTION The Lancet. ,vol. 314, pp. 1313- 1315 ,(1979) , 10.1016/S0140-6736(79)92808-3
W S Fields, N A Lemak, R F Frankowski, R J Hardy, Controlled trial of aspirin in cerebral ischemia. Stroke. ,vol. 8, pp. 301- 314 ,(1977) , 10.1161/01.STR.8.3.301
P. C. Elwood, A. L. Cochrane, M. L. Burr, P. M. Sweetnam, G. Williams, E. Welsby, S. J. Hughes, R. Renton, A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial Infarction BMJ. ,vol. 1, pp. 436- 440 ,(1974) , 10.1136/BMJ.1.5905.436
UlrichF. Gruber, François Duckert, Raimund Fridrich, Josef Rem, Joachim Torhorst, V.V. Kakkar, T.P. Corrigan, D.P. Fossard, I. Sutherland, J. Thirlwell, Prevention of fatal postoperative pulmonary embolism by low-dose heparin. The Lancet. ,vol. 309, pp. 898- ,(1977) , 10.1016/S0140-6736(77)91213-2
Ralph F. Frankowski, Noreen A. Lemak, William S. Fields, Robert J. Hardy, Robert H. Bigelow, Controlled trial of aspirin in cerebral ischemia. Circulation. ,vol. 62, ,(1980)
Mustard Jf, Packham Ma, Pharmacology of platelet-affecting drugs. Circulation. ,vol. 62, ,(1980)